{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T18:40:23Z","timestamp":1768675223124,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Chemotherapy induced cardio-toxicity has been recognized as a serious side effect since the first introduction to anthracyclines (ANT). Cardio-toxicity among patients with breast cancer is well studied but the impact on patients with sarcoma is limited, even though they are exposed to higher ANT doses. The commonly used term for cardio-toxicity is cancer therapeutics related cardiac dysfunction (CTRCD), defined as a left ventricular ejection fraction (LVEF) reduction of &gt;\u200910%, to a value below 53%. The aim of our study was to estimate the prevalence of CTRCD in patients diagnosed with sarcoma and to describe the baseline risk factors and echocardiography parameters among that population.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Data were collected as part of the Israel Cardio-Oncology Registry (ICOR), enrolling all patients evaluated in the cardio-oncology clinic at our institution. The registry was approved by the local ethics committee and is registered in <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link> (Identifier: NCT02818517). All sarcoma patients were enrolled and divided into two groups - CTRCD group vs. non-CTRCD group.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among 43 consecutive patients, 6 (14%) developed CTRCD. Baseline cardiac risk factors were more frequent among the non-CTRCD group. Elevated left ventricular end systolic diameter and reduced Global Longitudinal Strain were observed among the CTRCD group. During follow-up, 2 (33%) patients died in the CTRCD group vs. 3 (8.1%) patients in the non-CTRCD group.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>CTRCD is an important concern among patients with sarcoma, regardless of baseline risk factors. Echocardiography parameters may provide an early diagnosis of cardio-toxicity.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07104-9","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T07:02:49Z","timestamp":1593500569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardio-toxicity among patients with sarcoma: a cardio-oncology registry"],"prefix":"10.1186","volume":"20","author":[{"given":"Sivan","family":"Shamai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zach","family":"Rozenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Merimsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Derakhshesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonatan","family":"Moshkovits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Topilsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaron","family":"Arbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6541-9863","authenticated-orcid":false,"given":"Michal","family":"Laufer-Perl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"7104_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"7104_CR2","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","volume":"30","author":"RB Womer","year":"2012","unstructured":"Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, Marcus K, Sailer S, Healey JH, Dormans JP, Weiss AR. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's oncology group. J Clin Oncol. 2012;30:4148\u201354.","journal-title":"J Clin Oncol"},{"key":"7104_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/1097-0142(1967)20:3<333::AID-CNCR2820200302>3.0.CO;2-K","volume":"20","author":"C Tan","year":"1967","unstructured":"Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20:333\u201353.","journal-title":"Cancer."},{"key":"7104_CR4","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Munoz D, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, ESC Scientific Document Group. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768\u2013801.","journal-title":"Eur Heart J"},{"key":"7104_CR5","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, JM DC, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalh\u00e3es A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911\u201339.","journal-title":"J Am Soc Echocardiogr"},{"key":"7104_CR6","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","volume":"137","author":"LS Mehta","year":"2018","unstructured":"Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, Pi\u00f1a IL, Volgman AS. Cardiovascular disease and breast Cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137:e30\u201366.","journal-title":"Circulation."},{"key":"7104_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/CLEP.S100779","volume":"8","author":"S Shantakumar","year":"2016","unstructured":"Shantakumar S, Olsen M, Vo TT, Norgaard M, Pedersen L. Cardiac dysfunction among soft tissue sarcoma patients in Denmark. Clin Epidemiol. 2016;8:53\u20139.","journal-title":"Clin Epidemiol"},{"key":"7104_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/ehjci\/jex033","volume":"18","author":"C Santoro","year":"2017","unstructured":"Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C, de Simone G, Trimarco B, De Placido S, Galderisi M. 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017;18:930\u20136.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"7104_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1\u201339 e14.","journal-title":"J Am Soc Echocardiogr"},{"key":"7104_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/ejechocard\/jep153","volume":"11","author":"SG Teo","year":"2010","unstructured":"Teo SG, Yang H, Chai P, Yeo TC. Impact of left ventricular diastolic dysfunction on left atrial volume and function: a volumetric analysis. Eur J Echocardiogr. 2010;11:38\u201343.","journal-title":"Eur J Echocardiogr"},{"key":"7104_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","volume":"7","author":"RM Lang","year":"2006","unstructured":"Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79\u2013108.","journal-title":"Eur J Echocardiogr"},{"key":"7104_CR12","first-page":"392","volume":"18","author":"C Charbonnel","year":"2017","unstructured":"Charbonnel C, Convers-Domart R, Rigaudeau S, Taksin AL, Baron N, Lambert J, Ghez S, Georges JL, Farhat H, Lambert J, Rousselot P, Livarek B. Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity. Eur Heart J Cardiovasc Imaging. 2017;18:392\u2013401.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"7104_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","volume":"107","author":"H Sawaya","year":"2011","unstructured":"Sawaya H, Sebag IA, Plana JC, Anuzzi JL, Ky B, Cohen V, Gosavi S, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375\u201380.","journal-title":"Am J Cardiol"},{"key":"7104_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ihj.2012.12.004","volume":"65","author":"M Bansal","year":"2013","unstructured":"Bansal M, Kasliwal RR. How do I do it? Speckle-tracking echocardiography. Indian Heart J. 2013;65:117\u201323.","journal-title":"Indian Heart J"},{"key":"7104_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/clc.4960120610","volume":"12","author":"BA Weinberg","year":"1989","unstructured":"Weinberg BA, Conces DJ Jr, Waller BF. Cardiac manifestations of noncardiac tumors Part II: Direct effects. Clin Cardiol. 1989;12:347\u201354.","journal-title":"Clin Cardiol"},{"key":"7104_CR16","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland \u00c5, Stor\u00e5s TH, Hagve TA, R\u00f8sj\u00f8 H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671\u201380.","journal-title":"Eur Heart J"},{"key":"7104_CR17","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M, Dom\u00e8nech A, Ortiz-P\u00e9rez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monz\u00f3 M, Esteve J. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hEmopathies). J Am Coll Cardiol. 2013;61:2355\u201362.","journal-title":"J Am Coll Cardiol"},{"key":"7104_CR18","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","volume":"60","author":"S Seicean","year":"2012","unstructured":"Seicean S, Seicean A, Plana J, Budd T, Marwick T. Effect of statin therapy on the risk for incident heart failure in patients with breast Cancer receiving Anthracycline chemotherapy. J Am Coll Cardiol. 2012;60:2384\u201390.","journal-title":"J Am Coll Cardiol"},{"key":"7104_CR19","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jcmg.2018.06.004","volume":"11","author":"JH Jordan","year":"2018","unstructured":"Jordan JH, Todd RM, Vasu S, Hundley WG. Cardiovascular magnetic resonance in the oncology patient. JACC Cardiovasc Imaging. 2018;11:1150\u201372.","journal-title":"JACC Cardiovasc Imaging"},{"key":"7104_CR20","doi-asserted-by":"publisher","first-page":"e0175544","DOI":"10.1371\/journal.pone.0175544","volume":"12","author":"A Boyd","year":"2017","unstructured":"Boyd A, Stoodley P, Richards D, Hui R, Harnett P, Vo K, Marwick T, Thomas L. Anthracyclines induce early changes in left ventricular systolic and diastolic function: a single Centre study. PLoS One. 2017;12:e0175544.","journal-title":"PLoS One"},{"key":"7104_CR21","doi-asserted-by":"crossref","unstructured":"Reichardt P, Tabone MD, Mora J, Morland B, Jones RL. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. 2018;14(25):2663\u201376.","DOI":"10.2217\/fon-2018-0210"},{"issue":"12","key":"7104_CR22","first-page":"5477","volume":"33","author":"T Berghmans","year":"2013","unstructured":"Berghmans T, Lafitte JJ, Scherpereel A, Paesmans M, Lecomte J, Marco VG, Meert AP, Leclercq N. Sculier JP; European lung Cancer working party. An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC. Anticancer Res. 2013;33(12):5477\u201382.","journal-title":"Anticancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07104-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07104-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07104-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T23:19:36Z","timestamp":1625008776000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07104-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7104"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07104-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"assertion":[{"value":"6 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The registry was approved by the local ethics committee of the Tel Aviv Sourasky Medical Center, Israel (Identifier: 0228\u201316-TLV) and is registered in  (Identifier: NCT02818517) All patients signed an informed consent at the first visit in the clinic and are then followed prospectively.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"609"}}